Published in Hepatitis Weekly, September 16th, 2002
The trials mark an important milestone because, for the first time in the U.S., Roche's PCR nucleic acid amplification technology (NAT) test will be evaluated for its safety and effectiveness in screening blood donations for the hepatitis B virus (HBV). In the process, researchers expect to gain a clearer understanding of the prevalence of HBV.
"The clinical trials of the AmpliScreen test will help us learn more about HBV by identifying cases earlier in the course of infection," said Paul V. Holland, MD, chief executive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.